• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/14/25 4:08:09 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRTX alert in real time by email
    vrtx-20250514
    0000875320VERTEX PHARMACEUTICALS INC / MAfalse00008753202025-05-142025-05-14

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported) May 14, 2025

    Vertex Pharmaceuticals Incorporated
    (Exact name of registrant as specified in its charter)
    Massachusetts
    000-19319
    04-3039129
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)
    50 Northern Avenue
    Boston, Massachusetts 02210
    (Address of principal executive offices) (Zip Code)

    (617) 341-6100
    (Registrant's telephone number, including area code)


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading Symbol
    Name of each exchange on which registered
    Common Stock, $0.01 Par Value Per Share
    VRTX
    The Nasdaq Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.07  Submission of Matters to a Vote of Security Holders
    The annual meeting of shareholders of Vertex Pharmaceuticals Incorporated (the "Company") was held on May 14, 2025 (the "Annual Meeting"). Set forth below are the voting results for each of the proposals submitted to a vote of the Company's shareholders at the Annual Meeting:
    Proposal No. 1: Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2026:
    ForAgainstAbstainNon-Votes
    Sangeeta Bhatia224,220,1151,944,29377,82810,235,401
    Lloyd Carney217,229,0478,930,15083,03910,235,401
    Alan Garber222,204,6083,955,76481,86410,235,401
    Reshma Kewalramani225,606,258543,39892,58010,235,401
    Michel Lagarde223,304,0432,856,08082,11310,235,401
    Jeffrey Leiden220,817,1755,347,12277,93910,235,401
    Diana McKenzie224,648,1371,516,17477,92510,235,401
    Bruce Sachs211,582,89514,580,87578,46610,235,401
    Jennifer Schneider225,303,813859,65078,77310,235,401
    Nancy Thornberry223,303,1762,862,34476,71610,235,401
    Suketu Upadhyay224,313,8281,839,54288,86610,235,401
    Proposal No. 2: Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025:
    ForAgainstAbstainNon-Votes
    229,386,0376,859,300232,3000
    Proposal No. 3: Based upon the following votes, the shareholders approved, on an advisory basis, the 2024 compensation program for the Company's named executive officers:
    ForAgainstAbstainNon-Votes
    208,886,38617,048,300307,55010,235,401
    Proposal No. 4: Based upon the following votes, the shareholders did not approve a shareholder proposal regarding excessive golden parachutes:
    ForAgainstAbstainNon-Votes
    84,117,100141,606,344518,79210,235,401





    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    VERTEX PHARMACEUTICALS INCORPORATED
    (Registrant)
    Date: May 14, 2025
    /s/ Jonathan Biller
    Jonathan Biller
    Executive Vice President, Chief Legal Officer

    Get the next $VRTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VRTX

    DatePrice TargetRatingAnalyst
    5/7/2025Outperform → Peer Perform
    Wolfe Research
    5/6/2025$503.00Outperform → Market Perform
    Leerink Partners
    4/22/2025$535.00Overweight
    Cantor Fitzgerald
    2/12/2025$408.00 → $424.00Sell → Hold
    Canaccord Genuity
    2/11/2025Sell → Hold
    Canaccord Genuity
    1/30/2025$460.00Overweight → Equal Weight
    Wells Fargo
    12/20/2024$600.00 → $535.00Buy
    H.C. Wainwright
    12/19/2024Outperform → Perform
    Oppenheimer
    More analyst ratings

    $VRTX
    SEC Filings

    See more
    • SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

      144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      5/21/25 4:58:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Other Events

      8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      5/19/25 4:24:32 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      5/14/25 4:08:09 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

      For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

      1/30/25 5:46:14 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

      For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

      12/8/23 11:12:21 AM ET
      $BLUE
      $VRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

      Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling

      8/4/23 4:36:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Upadhyay Suketu

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      7/17/25 4:09:19 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sachs Bruce I

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      7/17/25 4:04:16 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Mckechnie Duncan claimed ownership of 16,130 shares (SEC Form 3)

      3 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      7/2/25 4:20:57 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis

      - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and superior in reducing sweat chloride compared to TRIKAFTA - -  Approximately 3,800 people in Canada are now eligible for ALYFTREK, with up to 60 people potentially eligible for a medicine that treats the underlying cause of their disease for the first time - TORONTO, July 22, 2025 /CNW/ - Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic

      7/22/25 12:55:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company. The honor recognizes JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain, as a groundbreaking health care technology. "We are honored to be recognized at Premier's 2025 Innovation Celebration. This reflects our unwavering commitment to bringing innovative medicines, like JOURNAVX — a non-opioid and the first new class of pain medicine approved in decades — to patients with significant unmet

      7/14/25 8:30:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

      NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades (https://ibn.fm/dyQrw). By 2050, the American Cancer Society estimates that annual cancer diagnoses will reach 35 million. While advances in treatment have improved outcomes for some patients, the demand for more effective therapies remains urgent — and the opportunity for innovation and market impact is significant. Calidi Biotherapeutics Inc. (NYSE:CLDI) (Profile) is taking a bold approach to this challenge with a next-generation pl

      7/9/25 8:30:00 AM ET
      $CLDI
      $CRSP
      $CTMX
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $VRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vertex Pharma downgraded by Wolfe Research

      Wolfe Research downgraded Vertex Pharma from Outperform to Peer Perform

      5/7/25 8:37:12 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharma downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Vertex Pharma from Outperform to Market Perform and set a new price target of $503.00

      5/6/25 8:04:29 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Vertex Pharma with a new price target

      Cantor Fitzgerald resumed coverage of Vertex Pharma with a rating of Overweight and set a new price target of $535.00

      4/22/25 7:35:34 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Financials

    Live finance-specific insights

    See more
    • Vertex to Announce Second Quarter 2025 Financial Results on August 4th

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived we

      7/8/25 4:00:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Reports First Quarter 2025 Financial Results

      — Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY®, ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

      5/5/25 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex to Announce First Quarter 2025 Financial Results on May 5th

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals First Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast

      4/7/25 4:05:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Vertex Appoints Nancy Thornberry to its Board of Directors

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical

      12/5/23 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Appoints Michel Lagarde to its Board of Directors

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of

      10/5/23 8:00:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa

      8/29/23 9:00:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      4/10/24 12:14:10 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      2/13/24 5:17:31 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      2/9/24 6:19:03 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care